Abstract
Giulia Lo Russo, Alicia Paini, Andrew Paul Worth
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1007/978-1-4939-1115-8_1
10.1007/978-1-4939-1115-8_1
Mechanisms of immunotoxicity: stressors and evaluators
10.3390/ijms22158242 · 2021
10.1002/0471140856.tx1801s67
10.1002/0471140856.tx1801s67
Development of a testing battery to assess chemical-induced immunotoxicity: National toxicology program’s guidelines for immunotoxicity evaluation in mice
10.1016/0272-0590(88)90247-3 · 1988
Risk assessment in immunotoxicology I. Sensitivity and predictability of immune tests
10.1016/0272-0590(92)90047-l · 1992
Approaches and considerations for the assessment of immunotoxicity for environmental chemicals: a workshop summary
10.1016/j.yrtph.2013.11.012 · 2014
10.1007/978-1-4939-8549-4_3
10.1007/978-1-4939-8549-4_3
Chemical-induced contact allergy: from mechanistic understanding to risk prevention
10.1007/s00204-018-2283-z · 2018
The 21st Century movement within the area of skin sensitization assessment: From the animal context towards current human-relevant in vitro solutions
10.1016/j.yrtph.2019.104445 · 2019
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
Immunotoxicology: opportunities for non-animal test development
10.1177/026119290903700409 · 2009
10.14573/altex.2013.4.411
10.14573/altex.2013.4.411
Optimization of the IL-2 Luc assay for immunosuppressive drugs: a novel in vitro immunotoxicity test with high sensitivity and predictivity
10.1007/s00204-021-03101-4 · 2021
The use of in vitro systems for evaluating immunotoxicity: the report and recommendations of an ECVAM workshop
10.1080/15476910590965832 · 2005
In vitro immune organs-on-chip for drug development: a review
10.3390/pharmaceutics10040278 · 2018
10.1039/d0em00291g
10.1039/d0em00291g
Per- and polyfluoroalkyl substances in water and wastewater: a critical review of their global occurrence and distribution
10.1016/j.scitotenv.2021.151003 · 2022
10.1002/etc.4890
10.1002/etc.4890
10.2903/j.efsa.2020.6223
10.2903/j.efsa.2020.6223
Exposure to per-fluoroalkyl and polyfluoroalkyl substances leads to immunotoxicity: epidemiological and toxicological evidence
10.1038/s41370-018-0097-y · 2019
Perfluorinated compounds: Emerging POPs with potential immunotoxicity
10.1016/j.toxlet.2014.01.038 · 2014
Cord blood gene expression supports that prenatal exposure to perfluoroalkyl substances causes depressed immune functionality in early childhood
10.3109/1547691x.2015.1029147 · 2016
Perfluoroalkyl substances exposure and immunity, allergic response, infection, and asthma in children: review of epidemiologic studies
10.1016/j.heliyon.2021.e08160 · 2021
10.3390/ijerph14070691
10.3390/ijerph14070691
Serum vaccine antibody concentrations in children exposed to perfluorinated compounds
10.1001/jama.2011.2034 · 2012
Serum vaccine antibody concentrations in adolescents exposed to perfluorinated compounds
10.1289/ehp275 · 2017
Internal exposure to perfluoroalkyl substances (PFASs) and biological markers in 101 healthy 1-year-old children: associations between levels of perfluorooctanoic acid (PFOA) and vaccine response
10.1007/s00204-020-02715-4 · 2020
Prenatal exposure to perfluoroalkyl substances is associated with lower hand, foot and mouth disease viruses antibody response in infancy: Findings from the Guangzhou Birth Cohort Study
10.1016/j.scitotenv.2019.01.325 · 2019
Antibody response to booster vaccination with tetanus and diphtheria in adults exposed to perfluorinated alkylates
10.3109/1547691x.2015.1067259 · 2016
Association between prenatal exposure to perfluorinated compounds and symptoms of infections at age 1–4years among 359 children in the Odense Child Cohort
10.1016/j.envint.2016.08.026 · 2016
Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood
10.3109/1547691x.2012.755580 · 2013
Serum perfluoroalkyl substances, vaccine responses, and morbidity in a cohort of guinea-bissau children
10.1289/ehp6517 · 2020
Serum perfluoroalkyl substances (PFAS) and risk of asthma and various allergies in adolescents. The Tromsø study Fit Futures in Northern Norway
10.1016/j.envres.2018.11.005 · 2019
Perfluoroalkyl substances and food allergies in adolescents
10.1016/j.envint.2015.12.020 · 2016
Perfluoroalkyl Substances (PFAS) and their effects on the placenta, pregnancy, and child development: a potential mechanistic role for placental peroxisome proliferator-activated receptors (PPARs)
10.1007/s40572-020-00279-0 · 2020
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation
10.1007/s000110050622 · 2000
Mediating roles of PPARs in the effects of environmental chemicals on sex steroids
10.1155/2017/3203161 · 2017
In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs)
10.1016/j.taap.2011.11.004 · 2012
10.1093/bib/bby043
10.1093/bib/bby043
Continuous petri nets and microRNA analysis in melanoma
10.1109/tcbb.2017.2733529 · 2018
Optimal vaccination schedule search using genetic algorithm over MPI technology
10.1186/1472-6947-12-129 · 2012
10.2903/j.efsa.2017.4658
10.2903/j.efsa.2017.4658 · doi-reference
Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate
10.1093/toxsci/kft269 · doi-reference
In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs)
10.1016/j.taap.2010.11.004 · doi-reference
Perfluoroalkyl and polyfluoroalkyl substances and indicators of immune function in children aged 12–19 y: National Health and Nutrition Examination Survey
10.1038/pr.2015.213 · doi-reference
Generation of digital patients for the simulation of tuberculosis with UISS-TB
10.1186/s12859-020-03776-z · doi-reference
10.5121/ijdps.2011.2202
10.5121/ijdps.2011.2202 · doi-reference
10.1016/j.it.2006.06.007
10.1016/j.it.2006.06.007 · doi-reference
The mutation patterns in B-cell immunoglobulin receptors reflect the influence of selection acting at multiple time-scales
10.1098/rstb.2014.0242 · doi-reference
10.1016/b978-0-12-801238-3.00118-5
10.1016/b978-0-12-801238-3.00118-5 · doi-reference
10.1016/b978-0-12-385245-8.00005-4
10.1016/b978-0-12-385245-8.00005-4 · doi-reference
The Bystander effect
10.1097/00004032-200307000-00008 · doi-reference
10.1146/annurev.biochem.76.061705.090740
10.1146/annurev.biochem.76.061705.090740 · doi-reference
10.1016/s0091-6749(95)70025-0
10.1016/s0091-6749(95)70025-0 · doi-reference
Modeling and Simulating Carcinogenesis
10.1016/b978-0-12-805364-5.00012-3 · doi-reference
The Ornstein-Uhlenbeck process as a model of a low pass filtered white noise
10.1088/0026-1394/45/6/s17 · doi-reference
Distances Between Bent Functions
10.1016/b978-0-12-802318-1.00011-x · doi-reference
10.1016/0025-5564(80)90017-6
10.1016/0025-5564(80)90017-6 · doi-reference
The immune system, adaptation, and machine learning
10.1016/0167-2789(86)90240-x · doi-reference
Exact string matching algorithms: survey, issues, and future research directions
10.1109/access.2019.2914071 · doi-reference
10.3389/fimmu.2014.00461
10.3389/fimmu.2014.00461 · doi-reference
Adhesion of bacteria to surfaces and biofilm formation on medical devices
10.1016/b978-0-08-100382-4.00003-4 · doi-reference
Implementation of a regulatory gene network to simulate the TH1/2 differentiation in an agent-based model of hypersensitivity reactions
10.1093/bioinformatics/btn135 · doi-reference
10.1007/978-1-4419-9863-7_283
10.1007/978-1-4419-9863-7_283 · doi-reference
Beyond hot spots: biases in antibody somatic hypermutation and implications for vaccine design
10.3389/fimmu.2018.01876 · doi-reference
Major histocompatibility complex classI-restricted antigen processing and presentation: Van Kaer : MHC class I-restricted antigen processing
10.1034/j.1399-0039.2002.600101.x · doi-reference
Immunoglobulin and other surface antigens of cells of the immune system
10.1084/jem.134.4.815 · doi-reference
10.1007/978-1-4684-5799-5_21
10.1007/978-1-4684-5799-5_21 · doi-reference
10.1111/tri.13475
10.1111/tri.13475 · doi-reference
10.1038/nri3712
10.1038/nri3712 · doi-reference
The immune system
10.1042/ebc20160017 · doi-reference
In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform
10.1186/s12859-020-03872-0 · doi-reference
10.1007/978-3-319-27833-9_5
10.1007/978-3-319-27833-9_5 · doi-reference
10.1109/mis.2013.29
10.1109/mis.2013.29 · doi-reference
10.1002/wsbm.45
10.1002/wsbm.45 · doi-reference
Developing agent-based models of complex health behaviour
10.1016/j.healthplace.2018.08.022 · doi-reference
Agent-based modeling: Methods and techniques for simulating human systems
10.1073/pnas.082080899 · doi-reference
10.1007/10692956_2
10.1007/10692956_2 · doi-reference
Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance
10.1007/s40495-016-0059-9 · doi-reference
10.3389/fimmu.2019.01033
10.3389/fimmu.2019.01033 · doi-reference
10.1016/j.coi.2010.11.010
10.1016/j.coi.2010.11.010 · doi-reference